These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30158337)

  • 1. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
    Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
    Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
    MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
    Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
    Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
    Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
    Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-month stability study of a biosimilar of infliximab (Remsima
    Vieillard V; Astier A; Sauzay C; Paul M
    Ann Pharm Fr; 2017 Jan; 75(1):17-29. PubMed ID: 27659414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.
    Pisupati K; Tian Y; Okbazghi S; Benet A; Ackermann R; Ford M; Saveliev S; Hosfield CM; Urh M; Carlson E; Becker C; Tolbert TJ; Schwendeman SP; Ruotolo BT; Schwendeman A
    Anal Chem; 2017 May; 89(9):4838-4846. PubMed ID: 28365979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
    Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
    MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical characterization of Remsima.
    Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
    MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
    Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
    Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.
    Sharma A; Khante S; Mahadik KR; Gaikwad VL
    Ther Innov Regul Sci; 2020 Sep; 54(5):965-977. PubMed ID: 31933180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
    Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
    J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
    Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
    MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
    Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
    J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of CT-P13: an infliximab biosimilar.
    McKeage K
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.